Приказ основних података о документу
Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines
dc.creator | Ljujić, Mila | |
dc.creator | Mijatović, Sanja | |
dc.creator | Bulatović, Mirna Z. | |
dc.creator | Mojic, Marija | |
dc.creator | Maksimović-Ivanić, Danijela | |
dc.creator | Radojković, Dragica | |
dc.creator | Topić, Aleksandra | |
dc.date.accessioned | 2019-09-02T12:01:33Z | |
dc.date.available | 2019-09-02T12:01:33Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1219-4956 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2964 | |
dc.description.abstract | Increased circulating alpha-1-antitrypsin (AAT) correlates with cancer stage/aggressiveness, but its role in cancer biology is unclear. We revealed antagonistic effect of AAT to cisplatin-induced cytotoxicity in prostate (PC3) and melanoma (A375) cancer cell lines. Moreover, AAT abrogated cytotoxicity of MEK inhibitor U0126 in PC3 cell line. Weaker antagonistic effect of AAT on cytotoxicity of PI3/Akt and NF-kB inhibitors was also observed. In addition, cisplatin increased AAT gene expression in transfected PC3 cells. However, AAT derived from transfected PC3 cells did not antagonize cisplatin-induced cytotoxicity. In conclusion, these results suggest possible association between high circulating AAT and cisplatin resistance. | en |
dc.publisher | Springer, Dordrecht | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173013/RS// | |
dc.rights | restrictedAccess | |
dc.source | Pathology & Oncology Research | |
dc.title | Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Љујић, Мила; Максимовић-Иванић, Данијела; Радојковић, Драгица; Мојиц, Марија; Топиц, Aлександра; Булатовић, Мирна З.; Мијатовић, Сања; | |
dc.citation.volume | 23 | |
dc.citation.issue | 2 | |
dc.citation.spage | 335 | |
dc.citation.epage | 343 | |
dc.citation.other | 23(2): 335-343 | |
dc.citation.rank | M22 | |
dc.identifier.wos | 000399000200014 | |
dc.identifier.doi | 10.1007/s12253-016-0104-3 | |
dc.identifier.pmid | 27617337 | |
dc.identifier.scopus | 2-s2.0-85016626907 | |
dc.type.version | publishedVersion |